Navigation Links
PRA International Hosts Audio Conference on Site and Patient Recruitment
Date:7/15/2010

RALEIGH, N.C., July 15 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, will host an audio conference on the best practices for increasing clinical trial site and patient recruitment on 22 July 2010 at 11:30 am (EDT). PRA's senior vice president of Scientific and Medical Affairs, Kent Thoelke, will be the presenter.

Mr. Thoelke will discuss how the key to successful recruitment is using the right data and algorithms to locate the target patient population. The session will also review the top data-driven processes that can lead to fewer non-productive trial sites, shorter development timelines, greater patient recruitment and lower drug development costs.

Mr. Thoelke has 20 years of experience executing all aspects of global studies and directing programs within the biotech, pharma and CRO industries. He oversees PRA's Scientific and Medical Affairs unit, which includes our Therapeutic Expertise group as well as medical monitoring and patient recruitment. A leader in the development of evidence-based approaches in clinical research, Mr. Thoelke specializes in leveraging data to more effectively target patient accrual.

Comprised of board-certified physicians and industry experts, PRA's Therapeutic Expertise group provides scientific and medical expertise for global clinical development. The group covers a broad range of therapeutic areas and supports the operational delivery of clinical services. PRA provides services through all phases of drug development and in clinical medicine, biostatistics and regulatory submission strategies.

For more information about this audio conference, navigate to

SOURCE PRA International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences
2. Bayer HealthCare Announces Recipients of 2010 WFH International Hemophilia Nursing Fellowship
3. International Drug & Explosives Detection Company Identa Corp Reports on New USA Marketing Representative
4. Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimers Association International Conference on Alzheimers Disease
5. Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair
6. Bacterin International Holdings, Inc. Completes Merger and $7.5 Million Raise
7. OXIS International Assumes Control and Exploitation Rights to Key L-Ergothioneine Patent Filing Representing a Major Market Opportunity
8. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
9. Serono Symposia International Foundation in Collaboration With ESHRE Announces Public Competition in Reproductive Medicine
10. Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International
11. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 /PRNewswire-iReach/ -- Phoenix Houses of California ... organization, is hosting its tenth annual "Triumph For Teens" ... 6, 2013.  More than 300 people are expected to ... residential treatment centers, family therapy, and prevention programs of ... have positive influences on the health and welfare of our ...
(Date:5/24/2013)... , May 24, 2013  Heska Corporation (NASDAQ: HSKA, ... and specialty products, announced today that Dr. Robert ... and Jason Napolitano , executive vice president ... Marcum MicroCap Conference, which is being held May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...
(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer").  On 20 May 2013, ...
Breaking Medicine Technology:Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9
... Amgen (Nasdaq: AMGN ) today announced results ... treatment for advanced cancer patients with bone metastases in ... (zoledronic acid). These results underscore the efficacy profile of ... bone metastases from advanced breast cancer, as well as ...
... Dec. 10, 2010 Syndax Pharmaceuticals, Inc., a clinical-stage ... on entinostat, an orally bioavailable, highly selective, class I ... cancer. The data are being presented as oral poster ... 8 through December 12 in San Antonio Texas. ...
Cached Medicine Technology:Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 2Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 3Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 4Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 5Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 6Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 7Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 8Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 9Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 10Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 11Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 12Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 13Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer 2Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer 3Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer 4
(Date:5/24/2013)... Compromise is often cited as crucial for relationships, ... sleep and comfort. However, many couples find themselves facing dilemmas ... this can cause added stress, lost sleep, and some resentment. ... common issues in their latest article on the subject. ... What to do When You Disagree on the Best Mattress ...
(Date:5/24/2013)... York, New York (PRWEB) May 24, 2013 ... the 2010 DePuy hip recall continue to move forward ... According to documents filed in California’s San Francisco ... been seeking an expedited trial of her DePuy hip ... (Tilman v. DePuy Orthopaedics, Inc., et al., No. CGC11508806; ...
(Date:5/24/2013)... 24, 2013 KC and Monica Craichy, Founders ... for FreeRide836. Their oldest sons, Kyle and Austin Craichy, will ... family and several professional kiteboarders. , KC Craichy said he ... has miraculously come together such that virtually everyone who planned ... , 20 kite boarders will meet at Matheson Hammock Park ...
(Date:5/24/2013)... Calif.) (PRWEB) May 24, 2013 ... House Appropriators and the California congressional delegation, joined ... restore sequestered industry user fees paid to the ... to ensure that future across-the-board cuts will not ... of the FY14 Agriculture, Rural Development and FDA ...
(Date:5/24/2013)... Teams of highly respected Alzheimer,s researchers failed to replicate ... of this brain disease when they were published last ... results, presented online Feb. 9, 2012, suggested that the ... buildup of beta amyloid plaques (Aβ) a pathological ... mice. According to the authors of the 2012 report, ...
Breaking Medicine News(10 mins):Health News:What’s The Best Bed Offers Mattress & Sleep Solutions for Opposite Couples 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3
... Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates ... , NEW YORK, June 19, 2009 Forest Laboratories, ... from two global multi-center Phase III studies of ceftaroline for ... data in each of the pivotal trials (FOCUS I and ...
... Kenneth A. May, former CEO of FedEx Kinko,s, has been ... Dimes, it was announced today. , , "Ken May is ... Prematurity Campaign," said Dr. Jennifer L. Howse, President of the March ... work towards our goal of giving every baby a healthy start ...
... changes , FRIDAY, June 19 (HealthDay News) -- A key ... by British researchers, who suggest that their finding may lead ... King,s College London and Imperial College London helps explain why ... are remodeled and how these changes contribute to chronic asthma. ...
... The Center for Laser Surgery, Washington, DC has announced the ... recently FDA approved, is the first cosmetic neurotoxin available alongside ... The Center for Laser Surgery was ... Dysport. As Washington, DC, Maryland and Virginia,s largest and most ...
... , WASHINGTON, June 19 The Department of Veterans Affairs ... its award-winning health care system, is poised to welcome nearly ... the country by expanding access to health care enrollment for ... , , "This incremental approach to expanding enrollment ensures ...
... should be treated as a priority if offenders held in ... research from the University of Adelaide, Australia. Adelaide researchers ... health of young offenders undertaken in the USA, UK, Europe ... have been published in this month,s Australian Journal of ...
Cached Medicine News:Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 2Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 3Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 4Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 5Health News:Dysport Available! New Wrinkle Treatment in Washington, DC Offers Botox Alternative 2Health News:VA Reopening Health Care Enrollment to Thousands of Veterans 2Health News:Young offenders' health critical to rehabilitation 2Health News:Young offenders' health critical to rehabilitation 3
The Primus linear accelerator is a fully digital, technologically advanced radiation therapy treatment delivery system. It can be configured for delivery of routine, 3-D conformal or IMRT treatments....
... accelerators are true high-performance ... multileaf collimation and electronic ... enable you to perform ... IMRT treatments, as well ...
... Clinac EX accelerators ... with integrated Varian multileaf ... imaging systems which enable ... most advanced computer-driven IMRT ...
The Clinac C family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
Medicine Products: